Table 2.
Targeted therapies in glioblastoma.
| Target | Inhibitors | References |
|---|---|---|
| αvβ3 and αvβ5 integrin | Cilengitide | [72] |
| EGFR | Erlotinib, gefitinib, lapatinib, cetuximab, AEE788, EKB569, ZD6474 | [73] |
| PDGFR | Imatinib mesylate, sorafenib, SU011248, PTK787 | [74] |
| VEGFR | Sorafenib, valatanib, sunitinib, AEE788, AZD2171, ZD6474 | [75] |
| mTOR | Temsirolimus, everolimus, sirolimus, AP23573 | [76]. |
| PKC | Tamoxifen, enzastaurin | [77]. |
| Histone deacetylase | Depsipeptide, suberoylanilide hydroxamic acid | [78]. |
| Farnesyltransferase | Lonafarnib, tipifarnib | [79] |
| Hsp90 | 17-AAG | [80] |
| Histone deacetylase | Depsipeptide, suberoylanilide hydroxamic acid | [81] |
| Proteasome | Bortezomib | [82] |